PMID: 9661031Jul 14, 1998Paper

Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms

Antimicrobial Agents and Chemotherapy
A D KashubaA N Nafziger

Abstract

Achieving a peak aminoglycoside concentration (Cmax)/MIC of > or = 10 within 48 h of initiation of therapy for pneumonia caused by gram-negative organisms results in a 90% probability of therapeutic response by day 7. Targeting an MIC of 1 microgram/ml, empirical aminoglycoside loading doses of 348 (25th- to 75th-percentile range, 275 to 432) mg were calculated to obtain a Cmax/MIC of 10 in our patient population. Individualized pharmacokinetic monitoring coupled with MIC data should determine subsequent dosing regimens to minimize the potential for toxicity and maximize the probability of clinical response.

References

Apr 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·R J Sawchuk, D E Zaske
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jul 11, 1991·Antimicrobial Agents and Chemotherapy·J S BertinoB Rybicki
Feb 1, 1974·The Journal of Infectious Diseases·J KlasterskyD Weerts
Dec 1, 1971·The Journal of Infectious Diseases·G G Jackson, L J Riff
Oct 1, 1984·The American Journal of Medicine·R D MooreP S Lietman

❮ Previous
Next ❯

Citations

Jul 27, 2001·Fundamental & Clinical Pharmacology·F FauvelleG Trape
Dec 16, 2004·The Annals of Pharmacotherapy·Robert E ArianoSheryl A Zelenitsky
Feb 19, 2020·Pacing and Clinical Electrophysiology : PACE·M Rizwan SohailJohn N Catanzaro
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Loretta M Chiu, Guy W Amsden
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Effie L GillespieDavid P Nicolau
Sep 12, 2002·Pharmacotherapy·Allison Wood WallaceJoseph S Bertino
Feb 22, 2012·Scandinavian Journal of Infectious Diseases·Yoichi HirakiYoshiharu Karube
Mar 22, 2018·The Journal of Antimicrobial Chemotherapy·Karen E BowkerAlasdair P MacGowan
Jul 31, 2018·Chembiochem : a European Journal of Chemical Biology·Jinming GuanKarine Auclair
Jan 30, 2004·Journal of Clinical Pharmacy and Therapeutics·J F Peris-MartiM Gonzalez-Delgado
Dec 6, 2008·Therapeutic Drug Monitoring·Rhonda S ReaHoward Lee
Jun 8, 2000·Clinical Pharmacokinetics·D T Bearden, K A Rodvold
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Vincent H TamElizabeth A Coyle
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·Christine StrijackSheryl A Zelenitsky
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·A D KashubaJ S Bertino
Jan 22, 2020·Journal of the American Chemical Society·Sivan Louzoun ZadaMicha Fridman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.